47 related articles for article (PubMed ID: 38694660)
1. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
2. Frequency of Complete Remission With R-CHOP Therapy in Patients With Diffuse Large B Cell Lymphoma.
Hassan SU; Hussain S; Fakhar M; Ahmad A; Durrani F
Cureus; 2024 Apr; 16(4):e57368. PubMed ID: 38694660
[TBL] [Abstract][Full Text] [Related]
3. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
[TBL] [Abstract][Full Text] [Related]
4. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
5. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon
Welslau M; Kubuschok B; Topaly J; Otremba B; Wolff T; Bryn G
Ther Adv Hematol; 2023; 14():20406207231183765. PubMed ID: 37492394
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
[No Abstract] [Full Text] [Related]
7. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
8. A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy.
Wang P; Chen K; Wang J; Ni Z; Shang N; Meng W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9757-9765. PubMed ID: 37247082
[TBL] [Abstract][Full Text] [Related]
9. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
Herrera AF; Tracy S; Croft B; Opat S; Ray J; Lovejoy AF; Musick L; Paulson JN; Sehn LH; Jiang Y
Blood Adv; 2022 Mar; 6(6):1651-1660. PubMed ID: 35086141
[TBL] [Abstract][Full Text] [Related]
10. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.
Decruyenaere P; Offner F; Vandesompele J
Exp Hematol Oncol; 2021 Feb; 10(1):13. PubMed ID: 33593440
[TBL] [Abstract][Full Text] [Related]
11. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
[TBL] [Abstract][Full Text] [Related]
12. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
Ben-Barouch S; Kuruvilla J
Expert Opin Investig Drugs; 2020 Jan; 29(1):15-21. PubMed ID: 31847605
[No Abstract] [Full Text] [Related]
13. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
[TBL] [Abstract][Full Text] [Related]
14. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
